PMID- 36699564
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231129
IS  - 1178-6965 (Print)
IS  - 1178-6965 (Electronic)
IS  - 1178-6965 (Linking)
VI  - 16
DP  - 2023
TI  - Characteristics of Induced-Sputum Inflammatory Phenotypes in Adults with Asthma: 
      Predictors of Bronchial Eosinophilia.
PG  - 95-103
LID - 10.2147/JAA.S389402 [doi]
AB  - PURPOSE: The objectives of this study were, for patients attending a specialist 
      asthma clinic at a tertiary care hospital, to determine, from sputum induction 
      (SI), proportions of bronchial inflammatory phenotypes, demographic, clinical and 
      functional characteristics of each phenotype, and the most accessible 
      non-invasive inflammatory marker that best discriminates between phenotypes. 
      PATIENTS AND METHODS: Included were 96 patients with asthma, attending a 
      specialist asthma clinic at a tertiary care hospital, who underwent testing as 
      follows: SI, spirometry, fractional exhaled nitric oxide (FeNO), blood 
      eosinophilia, total immunoglobulin E (IgE), and a skin prick test. RESULTS: SI 
      phenotypes were 46.9% eosinophilic, 33.3% paucigranulocytic, 15.6% neutrophilic, 
      and 4.2% mixed. No significantly different clinical or functional characteristics 
      were observed between the phenotypes. A positive correlation was observed between 
      SI eosinophilia and both emergency visits in the last 12 months (p = 0.041; r = 
      0.214) and FeNO values (p = 0.000; r = 0.368). Blood eosinophilia correlated with 
      SI eosinophilia (p = 0.001; r = 0.362) and was the best predictor of bronchial 
      eosinophilia, followed by FeNO, and total blood IgE (area under the receiver 
      operating characteristic curve (AUC-ROC) 72%, 65%, and 53%, respectively), 
      although precision was only fair. CONCLUSION: In consultations for severe asthma, 
      the most frequent phenotype was eosinophilic. Peripheral blood eosinophilia is a 
      reliable marker for discriminating between different bronchial inflammatory 
      phenotypes, is useful in enabling doctors to select a suitable biologic treatment 
      and so prevent asthma exacerbation, and is a better predictor of bronchial 
      eosinophilia than FeNO and IgE values.
CI  - (c) 2023 Crespo-Lessmann et al.
FAU - Crespo-Lessmann, Astrid
AU  - Crespo-Lessmann A
AUID- ORCID: 0000-0002-2238-6851
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Curto, Elena
AU  - Curto E
AUID- ORCID: 0000-0002-7291-0543
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Mateus Medina, Eder Freddy
AU  - Mateus Medina EF
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Palones, Esther
AU  - Palones E
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Belda Soler, Alicia
AU  - Belda Soler A
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Sanchez Maza, Soraya
AU  - Sanchez Maza S
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Soto-Retes, Lorena
AU  - Soto-Retes L
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Plaza, Vicente
AU  - Plaza V
AUID- ORCID: 0000-0003-2567-5496
AD  - Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, 
      Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica Sant Pau, Barcelona, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230119
PL  - New Zealand
TA  - J Asthma Allergy
JT  - Journal of asthma and allergy
JID - 101543450
EIN - J Asthma Allergy. 2023 Nov 20;16:1267-1268. PMID: 38022752
PMC - PMC9869783
OTO - NOTNLM
OT  - asthma
OT  - eosinophilia
OT  - phenotype
OT  - sputum induction
COIS- AC-L has received fees in the last 3 years for talks at meetings sponsored by 
      AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Ferrer, GlaxoSmithKline, MSD, 
      Novartis, Orion Pharma, and Sanofi, has received travel and attendance expenses 
      for conferences from Bial, Gebro, GlaxoSmithKline, Novartis, and TEVA, and has 
      received funds/grants for research projects from several state agencies, 
      non-profit foundations, and AstraZeneca and GlaxoSmithKline. EC reports 
      non-financial support from ALK, AstraZeneca, Novartis, and Menarini, personal 
      fees from Boehringer-Ingelheim and TEVA, and personal fees/non-financial support 
      from Chiesi outside the submitted work. This paper is part of the doctoral thesis 
      of EC. EP has received travel and attendance expenses for conferences from Gebro 
      Pharma, Chiesi, FAES Farma, Rovi, GlaxoSmithKline, and Sanofi, and has received 
      funds/grants for research projects from state agencies, non-profit foundations, 
      and Alpha Bioresearch. LS-R has received fees in the last 3 years for talks at 
      meetings sponsored by AstraZeneca, Diater, Chiesi, and GlaxoSmithKline, has 
      received travel and attendance expenses for conferences from Sanofi, 
      Allergy-Therapeutics, Hal Allergy, and FAES Farma, has acted as a consultant for 
      Sanofi, Stallergenes-Greer, GlaxoSmithKline, and AstraZeneca, and has received 
      funds/grants for research projects from Spanish Allergy and Clinical Immunology 
      Society (SEAIC), a non-profit foundation. VP has received fees in the last 3 
      years for talks at meetings sponsored by AstraZeneca, Boehringer-Ingelheim, Merck 
      Sharp & Dohme, and Chiesi, has received travel and attendance expenses for 
      conferences from AstraZeneca, Chiesi, and Novartis, has acted as a consultant for 
      ALK, AstraZeneca, Boehringer, Merck Sharp & Dohme, MundiPharma, and Sanofi, and 
      has received funds/grants for research projects from several state agencies, 
      non-profit foundations, and AstraZeneca, Chiesi and Menarini. EFMM and ABS and 
      SSM declare no conflicts of interest in this work.
EDAT- 2023/01/27 06:00
MHDA- 2023/01/27 06:01
PMCR- 2023/01/19
CRDT- 2023/01/26 02:47
PHST- 2022/09/09 00:00 [received]
PHST- 2022/12/19 00:00 [accepted]
PHST- 2023/01/26 02:47 [entrez]
PHST- 2023/01/27 06:00 [pubmed]
PHST- 2023/01/27 06:01 [medline]
PHST- 2023/01/19 00:00 [pmc-release]
AID - 389402 [pii]
AID - 10.2147/JAA.S389402 [doi]
PST - epublish
SO  - J Asthma Allergy. 2023 Jan 19;16:95-103. doi: 10.2147/JAA.S389402. eCollection 
      2023.